ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Arrowhead Pharma purchases land ahead of new manufacturing facility buildout
December 22, 2021New campus will support the company as it approaches potential commercialisation of its rapidly progressing clinical candidates. -
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
June 28, 2021Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT -
Arrowhead and Horizon enter up to $700m deal to develop RNAi drug
June 23, 2021Arrowhead Pharmaceuticals and Horizon Therapeutics have entered a global partnership and licence agreement to develop the former’s ribonucleic acid interference (RNAi) therapeutic, ARO-XDH. -
Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
March 28, 2018Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV
Pharma Sources Insight January 2025
